Werfen and Instrumentation Laboratory Acquire Accriva Diagnostics
By Labmedica International staff writers
Posted on 26 Jan 2017
Image: Werfen and Instrumentation Laboratory have acquired Accriva Diagnostics (Photo courtesy of iStock).
Werfen and its subsidiary Instrumentation Laboratory (IL) have acquired Accriva Diagnostics, which provides in vitro diagnostic (IVD) blood testing at the Point-of-Care (POC).
Werfen develops, manufactures and distributes IVD testing solutions, systems, reagents and software to hospitals and clinical laboratories around the world. An integral part of Werfen, IL develops and manufactures hemostasis, critical care, and patient blood management (PBM) products. The acquisition of Accriva, whose product portfolio includes coagulation, platelet aggregation, CO-Oximetry, and incision devices, will allow IL to further enhance its position in hospital-based POC hemostasis testing, POC critical care testing, and the hemostasis laboratory segment.
"Over the course of our 50-year history, we have demonstrated our strong commitment to expanding our IVD business through organic growth, complemented with highly strategic acquisitions," said Carlos Pascual, CEO at Werfen. "Like our recent acquisition of CA Casyso AG and its Tem subsidiaries, the acquisition of Accriva is exemplary of this commitment, as well as the confidence we have in our future together."
"By acquiring Accriva, we are expanding our product offering, expertise, and know-how in POC testing, particularly for hemostasis," said Ramon Benet, CEO at IL. "The addition of Accriva products to our strong critical care, hemostasis and PBM portfolios creates an even more comprehensive and integrated testing solution for hospital acute care settings and laboratories, further impacting positive clinical outcomes and reducing healthcare costs."